Tibet Aim Pharm

Tibet Aim Pharm EBIT per Share

The EBIT per Share of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 0.54 CNY. In the previous year, EBIT per Share was 0.37 CNY — a change of 45.06% (higher).

EBIT per Share

0.54CNY

YoY

45.06%

Last updated:

EBIT per Share of Tibet Aim Pharm is 2025 0.54 CNY. EBIT per Share of Tibet Aim Pharm was 2024 0.37 CNY. It decreases by 45.06% higher compared to the previous year.

The Tibet Aim Pharm EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
0.13 CNY
Jan 1, 2019
0.30 CNY
Jan 1, 2020
0.24 CNY
Jan 1, 2021
0.24 CNY
Jan 1, 2022
0.30 CNY
Jan 1, 2023
0.11 CNY
Jan 1, 2024
0.37 CNY
Jan 1, 2025
0.54 CNY
The Tibet Aim Pharm EBIT per Share history
YEAREBIT per ShareYoY
0.54CNY+45.06%
0.37CNY+246.65%
0.11CNY-63.61%
0.30CNY+22.53%
0.24CNY-0.58%
0.24CNY-17.86%
0.30CNY+132.93%
0.13CNY-61.48%
0.33CNY+8.96%
0.30CNY+5.95%
0.29CNY+73.51%
0.16CNY+110.46%
0.08CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

EBIT per Share of Tibet Aim Pharm is 0.54 CNY in 2025.

EBIT per Share of Tibet Aim Pharm changed from 0.37 CNY to 0.54 CNY, representing a 45.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm